Hostname: page-component-77c89778f8-vpsfw Total loading time: 0 Render date: 2024-07-19T22:02:47.326Z Has data issue: false hasContentIssue false
  • English
  • Français

Population-based Study of Medulloblastoma: Outcomes in Alberta from 1975 to 1996

Published online by Cambridge University Press:  02 December 2014

Gloria Roldán ,
Penny Brasher ,
Giacomo Vecil ,
Donna Senger ,
Barry Rewcastle ,
Gregory Cairncross ,
Peter Forsyth  and
Mark Hamilton
Gloria Roldán
Affiliation:
Department of Clinical Neurosciences, Foothills Medical Centre, University of Calgary Department of Oncology, Heritage Medical Research Building,Heritage Medical Research Building, Calgary, Alberta, Canada Clark Smith Integrated Brain Tumor Cancer Centre, Heritage Medical Research Building,Heritage Medical Research Building, Calgary, Alberta, Canada
Penny Brasher
Affiliation:
Department of Anatomic Pathology, Foothills Medical Centre, University of Calgary Department of Oncology, Heritage Medical Research Building,Heritage Medical Research Building, Calgary, Alberta, Canada Division of Population Health and Information, Heritage Medical Research Building,Heritage Medical Research Building, Calgary, Alberta, Canada
Giacomo Vecil
Affiliation:
Department of Neurosurgery, University of Texas, Health Science Center, San Antonio, Texas, USA.
Donna Senger
Affiliation:
Department of Clinical Neurosciences, Foothills Medical Centre, University of Calgary Department of Oncology, Heritage Medical Research Building,Heritage Medical Research Building, Calgary, Alberta, Canada
Barry Rewcastle
Affiliation:
Department of Clinical Neurosciences, Foothills Medical Centre, University of Calgary Department of Anatomic Pathology, Foothills Medical Centre, University of Calgary
Gregory Cairncross
Affiliation:
Department of Clinical Neurosciences, Foothills Medical Centre, University of Calgary Department of Oncology, Heritage Medical Research Building,Heritage Medical Research Building, Calgary, Alberta, Canada Clark Smith Integrated Brain Tumor Cancer Centre, Heritage Medical Research Building,Heritage Medical Research Building, Calgary, Alberta, Canada
Peter Forsyth*
Affiliation:
Department of Clinical Neurosciences, Foothills Medical Centre, University of Calgary Department of Oncology, Heritage Medical Research Building,Heritage Medical Research Building, Calgary, Alberta, Canada Clark Smith Integrated Brain Tumor Cancer Centre, Heritage Medical Research Building,Heritage Medical Research Building, Calgary, Alberta, Canada
Mark Hamilton
Affiliation:
Department of Clinical Neurosciences, Foothills Medical Centre, University of Calgary Division of Neurosurgery, Foothills Medical Centre, University of Calgary Clark Smith Integrated Brain Tumor Cancer Centre, Heritage Medical Research Building,Heritage Medical Research Building, Calgary, Alberta, Canada
*
Clark Smith Brain Tumor Center, Rm. 2AA19 Health Research Innovation Center, 3330 Hospital Drive NW, Calgary, Alberta, T2N 4N1, Canada
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background:

The purpose of this study was to determine incidence, survival rate, and prognostic factors as well as the frequency of Collins’ Law Violators (CLVs) in an unselected population of medulloblastoma patients. Collins’ Law dictates that ’cure’ of a child with a tumor occurs after a period that includes the child’s age at diagnosis plus 9 months.

Methods:

Using the Alberta Cancer Registry a population-based review identified 49 patients with medulloblastoma (19 adults, 30 children) diagnosed from 1975-96. Pathology was reviewed in all cases. All patients had surgical resection, followed by radiotherapy in 47 patients and chemotherapy in 17.

Results:

The overall 5-year survival was 50%. There was a trend for the extent of resection to be associated with a longer survival (Long rank test, p< 0.06) but this was not significant. Tumor recurrence occurred a median of 22.4 months (range, 6.4-192.3) after diagnosis and median survival after recurrence was 9.3 months (range, 0.4-64.9). The survival curve did not appear to plateau but was affected by tumor-related deaths in 3 (21.4%) of the 21 long-term survivors diagnosed in childhood. These three patients had recurrences a mean of 11.7 years after diagnosis and are designated as CLVs.

Conclusions:

The survival rate in an unselected population of patients with medulloblastoma is poor. Aggressive resection of the tumors prolongs survival. The Collins’ Law Violators were relatively common and we suggest this concept be abandoned in medulloblastoma.

Résumé:

<span class='bold'>RÉSUMÉ:</span><span class='bold'><span class='italic'>Contexte:</span></span>

Le but de cette étude était d’évaluer l’incidence, le taux de survie et les facteurs influençant le pronostic ainsi que la fréquence des contrevenants à la loi de Collins dans une population non sélectionnée de patients atteints de médulloblastome. Selon la loi de Collins, un enfant atteint d’une tumeur est guéri après un temps défini par l’âge de l’enfant au moment du diagnostic plus 9 mois.

<span class='bold'><span class='italic'>Méthodes:</span></span>

Nous avons identifié 49 patients atteints de médulloblastome (19 adultes et 30 enfants) dans le Alberta Cancer Registry, entre 1975 et 1996. L’anatomopathologie a été révisée dans tous les cas. Tous les patients avaient subi une résection chirurgicale suivie de radiothérapie chez 47 patients et de chimiothérapie chez 17 patients.

<span class='bold'><span class='italic'>Résultats:</span></span>

La survie globale à 5 ans était de 50%. La longueur de la survie avait tendance à être associée à l’étendue de la chirurgie, sans atteindre le seuil de la signification statistique (Long rank test, p < 0,06). La médiane de survie sans récidive était de 22,4 mois (écart de 6,4 à 192,3 mois) après le diagnostic et la survie médiane après la récidive était de 9,3 mois (écart de 0,4 à 64,9 mois). La courbe de suivie ne semblait pas atteindre de plateau et elle était influencée par le décès dû à la tumeur chez 3 des 21 survivants à long terme dont le diagnostic avait été posé dans l’enfance. La moyenne de survie sans récidive chez ces 3 patients était de 11,7 ans après le diagnostic et donc ils sont des contrevenants à la loi de Collins.

<span class='bold'><span class='italic'>Conclusion:</span></span>

Le taux de survie dans une population non sélectionnée de patients atteints de médulloblastome est faible. Une résection agressive de la tumeur prolonge la survie. Les contrevenants à la loi de Collins étaient relativement fréquents et nous proposons que ce concept soit abandonné en ce qui concerne le médulloblastome.

Type
Original Articles
Information
Canadian Journal of Neurological Sciences , Volume 35 , Issue 2 , May 2008 , pp. 210 - 215
Copyright
Copyright © The Canadian Journal of Neurological 2008

References

1. Cumberlin, RL, Luk, KH, Wara, WM, Sheline, GE, Wilson, CB. Medulloblastoma: treatment results and effect on normal tissues. Cancer. 1979; 43:1014–20.Google Scholar
2. Miltenburg, D, Louw, DF, Sutherland, GR. Epidemiology of childhood brain tumors. Can J Neurol Sci. 1996; 23:118–22.Google Scholar
3. Carrie, C, Lasset, C, Blay, JY, Nrgrier, S, Bouffet, E, Barbel, N, et al. Medulloblastoma in adults: survival and prognostic factors. Radiother Oncol. 1993; 29:301–7.CrossRefGoogle ScholarPubMed
4. Brandes, AA, Paris, MK. Review of the prognostic factors in medulloblastoma of children and adults. Crit Rev Oncol Hematol. 2004; 5:121–8.Google Scholar
5. Herrlinger, U, Steinbrecher, A, Rieger, J, Hau, P, Kortmann, RD, Meyermann, R, et al. Adult medulloblastoma: prognostic factors and response to therapy at diagnosis and at relapse. J Neurol. 2005; 252(3):291–9.Google Scholar
6. Eisenstat, DD. Clinical management of medulloblastoma in adults. Expert Rev Anticancer Ther. 2004; 4:795–802.CrossRefGoogle ScholarPubMed
7. Kopelson, G, Linggood, RM, Kleinman, GM. Medulloblastoma in adults: improved survival with supervoltage radiation therapy. Cancer. 1982; 49:1334–7.Google Scholar
8. Ribi, K, Relly, C, Landolt, MA, Alber, FD, Boltshauser, E, Grotzer, MA. Outcome of medulloblastoma in children: long-term complications and quality of life. Neuropediatrics. 2005; 36: 357–65.Google Scholar
9. Rutkauskiene, G, Labanauskas, L, Jarusevicius, L. The results of the treatment of childhood medulloblastoma with radiotherapy at Kaunas University of Medicine Hospital in 1994-2000. Medicina (Kaunas). 2006; 42:22–32.Google Scholar
10. Gajjar, A, Chintagumpala, M, Ashley, D, Kellie, S, Kun, LE, Merchant, TE, et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol. 2006; 7(10):813–20.Google Scholar
11. Packer, RJ, Gajjar, A, Vezina, G, Rorke-Adams, L, Burger, PC, Robertson, PL, et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol. 2006; 24(25): 4202–8.Google Scholar
12. Geyer, JR, Sposto, R, Jennings, M, Boyett, JM, Axtell, RA, Breiger, D, et al. Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children’s Cancer Group. J Clin Oncol. 2005; 23:7621–31.Google Scholar
13. Mulhern, RK, Palmer, SL, Merchant, TE, Wallace, D, Kocak, M, Brouwers, P, et al. Neurocognitive consequences of risk-adapted therapy for childhood medulloblastoma. J Clin Oncol. 2005; 23:5511–19.CrossRefGoogle ScholarPubMed
14. Grill, J, Sainte-Rose, C, Jouvet, A, Gentet, JC, Lejars, O, Frappaz, D, et al. Treatment of medulloblastoma with postoperative chemotherapy alone: an SFOP prospective trial in young children. Lancet Oncol. 2005; 6:573–80.Google Scholar
15. Rutkowski, S, Bode, U, Deinlein, F, Ottensmeier, H, Warmuth-Metz, M, Soerensen, N, et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N Engl J Med. 2005; 352:978–86.Google Scholar
16. Collins, VP. Wilms’ tumor: its behavior and prognosis. J Louisiana State Med Soc. 1955; 107:474–80.Google Scholar
17. Brown, WD, Tavare, CJ, Sobel, EL, Gilles, FH. The applicability of Collins’ Law to childhood brain tumors and its usefulness as a predictor of survival. Neurosurgery. 1995; 36:1093–6.Google Scholar
18. Paulino, AC. Collins’ law revisited: can we reliably predict the time to recurrence in common pediatric tumors? Pediatr Hematol Oncol. 2006; 23(1):81–6.CrossRefGoogle ScholarPubMed
19. Brown, WD, Tavare, J, Sobel, EL, Gilles, FH. Medulloblastoma and Collin’s law: a critical review of the concept of a period of risk for tumor recurrence and patient survival. Neurosurgery. 1995; 36:691–7.Google Scholar
20. Lefkowithz, IB, Packer, RJ, Ryan, SG, Shah, N, Alavi, J, Rorke, LB, et al. Late recurrence of primitive neuroectodermal tumor/ medulloblastoma. Cancer. 1988; 62(4):826–30.Google Scholar
21. World Health Organization, editors. International classification of diseases for oncology (ICD-0) 2. 1990 Geneva: World Health Organization.Google Scholar
22. World Health Organization, editors. International classification of diseases 9th revision clinical modification (ICD-9-CM) 8. 1991 Geneva: World Health Organization.Google Scholar
23. Cancer Programs Regulation. Alberta Reg. 242/1998. Database online. [updated 2006 September 26; cited 2006 October 10] Available from http://www.canlii.org/ab/laws/regu/1998r.242/20060926/whole.htmlGoogle Scholar
24. Burger, PC, Scheithauer, BW. Tumors of the nervous system, 3rd series. Washington D.C: Armed Forces Institute of Pathology; 1994.Google Scholar
25. Le, QT, Weil, MD, Wara, WM, Lamborn, KR, Prados, MD, Edwards, MS, et al. Adult medulloblastoma: an analysis of survival and prognostic factors. Cancer, J Sci Am. 1997; 3:238–45.Google ScholarPubMed
26. Chang, CH, Housepian, EM, Herbert, C. An operative staging system and a megavoltage radiotherapeutic technic for cerebellar medulloblastoma. Radiology. 1969; 93:1351–9.Google Scholar
27. Kaplan, EL, Meier, P. “Nonparametric estimation from incomplete observations.” J Am Stat Assoc. 1958; 53:457–81.Google Scholar
28. Mantel, N. The detection of disease clustering and a generalized regression approach. Cancer Res. 1967; 27:209–20.Google Scholar
29. Davis, FG, Freels, S, Grutsch, J, Barlas, S, Brem, S. Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on surveillance, Epidemiology, and End Results (SEER) data, 1973-1991. J Neurosurgery. 1998; 88:1–10.Google Scholar
30. Farwell, JR, Dohrmann, GJ, Flannery, JT. Medulloblastoma in childhood: an epidemiological study. J Neurosurgery. 1984; 61: 657–64.Google Scholar
31. Agerlin, N, Gjerris, F, Brincker, H, Haase, J, Laursen, H, Moller, KA, et al. Childhood medulloblastoma in Denmark 1960-1984. A population-based retrospective study. Childs Nerv Syst. 1999; 15(1):29–36.Google Scholar
32. Alston, RD, Newton, R, Kelsey, A, Newbould, MJ, Birch, JM, Lawson, B, et al. Childhood medulloblastoma in northwest England 1954 to 1997: incidence and survival. Dev Med Child Neurol. 2003; 45(5):308–14.Google Scholar
33. Nishio, S, Morioka, T, Takeshita, I, Fukui, M. Medulloblastoma: survival and late recurrence after the Collins’ risk period. Neurosurg Rev. 1997; 20(4):245–9.Google Scholar
34. Bloom, HJ G, Bessell, EM. Medulloblastoma in adults: a review of 47 patients treated between 1952 and 1981. Int J Radiat Oncol Biol Phys. 1990; 18:763–72.Google Scholar
35. Akay, KM, Izci, Y, Baysefer, A, Atabey, C, Kismet, E, Timurkaynak, E. Surgical outcomes of cerebellar tumors in children. Pediatr Neurosurg. 2004; 40:220–5.Google Scholar
36. Tabori, U, Sung, L, Hukin, J, Laperriere, N, Crooks, B, Carret, AS, et al. Distinctive clinical course and pattern of relapse in adolescents with medulloblastoma. Int J Radial Oncol Biol Phys. 2006; 64(2):402–7.Google Scholar
37. Robert, RO, Lynch, CF, Jones, MP, Hart, MN. Medulloblastoma: a population based study of 532 cases. J Neuropathol Exp Neurol. 1991; 50:134–44.Google Scholar
38. Cogen, PH, MacDonald, JD. Tumor suppressor genes and medulloblastoma. J Neurooncology. 1996; 29:103–12.Google Scholar
39. Malkin, D, Li, FP, Strong, LC, Fraumeni, JJ, Nelson, CE, Kin, DH, et al. Germline p53 mulations in a familial syndrome of breasl cancer, and other neoplasms. Science. 1990; 250: 1233–8.CrossRefGoogle Scholar
40. Uziel, T, Zindy, F, Xie, S, Lee, Y, Forget, A, Magdaleno, S, el al. The lumor suppressors Ink4c and p53 collaborate independently with Patched to suppress medulloblastoma formation. Genes Dev. 2005; 19:2656–7.Google Scholar
41. Badiali, M, Pession, A, Basso, G, Andreini, L, Rigobello, L, Gallassi, E, el al. N-myc and c-myc oncogenes amplification in medulloblastomas. Evidence of a particularly aggressive behavior of a lumor with c-myc amplification. Tumor. 1991; 77:118–21.Google Scholar
42. Tomlinson, FH, Jenkins, RB, Scheithauer, BW, Keelan, PA, Ritland, S, Parisi, JE, et al. Aggressive medulloblasloma with high-level N-myc amplification. Mayo Clinic Proceed. 1994; 69:359–65.Google Scholar
43. Kozmik, Z, Sure, U, Ruedi, D, Busslinger, M, Aguaai, A. Deregulated expression of PAX5 in medulloblastoma. Proc Nat’l Acad Sci USA. 1995; 92:5709–13.Google Scholar
44. Groodrich, LV, Milenkovic, L, Higgins, KM, Scott, MP. Altered neural cell fates and medulloblastoma in mouse patched mutants. Science. 1997; 277:1109–13.Google Scholar
45. Grolzer, MA, Janss, AJ, Fung, KM, Biegel, JA, Sutton, LN, Rorke, LB, et al. Trk C expression predicts good clinical outcome in primitive neuroeclodermal brain tumors. J Clin Oncol. 2000; 18:1027–35.Google Scholar
46. Pan, E, Pellarin, M, Holmes, E, Smirnov, I, Misra, A, Eberhart, CG, et al. Isochromosome 17q is a negative prognostic factor in poor-risk childhood medulloblastoma patients. Clin Cancer Res. 2005; 11:4733–40.Google Scholar
47. Thompson, MC, Fuller, C, Hogg, TL, Dalton, J, Finkelstein, D, Lau, CC, et al. Genomics identifies medulloblasloma subgroups that are enriched for specific genetic alterations. J Clin Oncol. 2006; 24:1924–31.Google Scholar